Buscar
Mostrando ítems 1-10 de 455
Why do we still have not a vaccine against chagas disease?
(Fundação Oswaldo Cruz / IOC, 2022)
Desarrollo de una vacuna profilactica de segunda generacion contra el papilomavirus humanoDevelopment of a second generation prophylactic vaccine against human papillomavirus
(Medicina (buenos Aires), 2011)
Human papillomaviruses (HPV) are the etiologic agent for cervical cancer (CC), the second cause of cancer death in women worldwide. It is estimated that half a million new cases are diagnosed each year, mostly in developing ...
Prophylactic and therapeutic vaccines against sporotrichosis. Feasibility and prospects
(2019-01-01)
Sporotrichosis is an emergent subcutaneous mycosis of humans and some animals caused by dimorphic fungi of the genus Sporothrix. The disease occurs worldwide but is endemic or hyperendemic in tropical and subtropical areas. ...
Cost-effectiveness of Prophylactic Zika Virus Vaccine in the Americas
(Centers Disease Control & Prevention, 2019-12-01)
Zika virus remains a major public health concern because of its association with microcephaly and other neurologic disorders in newborns. A prophylactic vaccine has the potential to reduce disease incidence and eliminate ...
Nanotechnology, Drug Delivery Systems and their Potential Applications in Hepatitis B Vaccines
(MedCrave, 2015-09)
Since the Nobel Prize in Physiology or Medicine 1976 Baruch Blumberg and Irving Millman developed the first prophylactic plasma-derived hepatitis B vaccine - also considered the world´s first cancer vaccine- so much progress ...
Immunity and vaccine development efforts against Trypanosoma cruzi
(Elsevier Science, 2019-12)
Trypanosoma cruzi (T. cruzi) is the causative agent for Chagas disease (CD). There is a critical lack of methods for prevention of infection or treatment of acute infection and chronic disease. Studies in experimental ...
Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine up to 8.4 years of follow-up
(Landes BioscienceAustinEUA, 2012)
DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS)
(PLoS, 2012)
Andes virus (ANDV) is the predominant cause of hantavirus pulmonary syndrome (HPS) in South America and the only hantavirus known to be transmitted person-to-person. There are no vaccines, prophylactics, or therapeutics ...
DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS)
(PLoS, 2012)
Andes virus (ANDV) is the predominant cause of hantavirus pulmonary syndrome (HPS) in South America and the only hantavirus known to be transmitted person-to-person. There are no vaccines, prophylactics, or therapeutics ...
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
(Nature Publishing GroupLondonInglaterra, 2006)